News Headlines

  1. Checkpoint Therapeutics Initiates Dose Expansion Portion Of Phase 1 Trial Of Anti-PD-L1 Antibody CK-301

    Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced the completion of the dose escalation portion of the ongoing Phase 1 clinical trial of CK-301, a fully human anti-PD-L1 antibody, in selected recurrent or metastatic cancers, and the initiation of the first dose expansion cohort, which is evaluating an 800 mg dose of CK-301 administered every two weeks.

  2. New Alzheimer's Association Report Reveals Sharp Increases In Alzheimer's Prevalence, Deaths And Cost Of Care

    For the second consecutive year, total payments to care for individuals living with Alzheimer's or other dementias are projected to surpass a quarter of a trillion dollars ($277 billion), which includes an increase of nearly $20 billion over last year, according to data reported in the Alzheimer's Association 2018 Alzheimer's Disease Facts and Figures report released today.

  3. VALNEVA Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate VLA15

    Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced positive Phase I interim results for its Lyme vaccine candidate, VLA15.

  4. The AdVance Study: A Landmark Natural History Study Of Adenovirus In Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden And Mortality Risk

    Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from AdVance, the first large, multi-center study of adenovirus (AdV) incidence, natural history, management and clinical outcomes in allogeneic hematopoietic cell transplant (allo-HCT) recipients.

  5. resTORbio Announces Formation Of Clinical Advisory Board

    resTORbio, announced the formation of a clinical advisory board (CAB) to support the continued development of the company’s novel therapeutics designed to treat aging-related organ dysfunction, including aging-related declines in immune, cardiac and neurologic function.

  6. Agios Announces First Patient Dosed With MAT2A Inhibitor AG-270 In Phase 1 Study In Patients With Advanced Solid Tumors Or Lymphoma With An MTAP Deletion

    Agios Pharmaceuticals, Inc. a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced dosing of the first patient in a Phase 1 study of AG-270, a first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor.

  7. Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of PROTECT Clinical Trial Of ProTmune™

    Fate Therapeutics, Inc.a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today additional clinical data from the Phase 1 stage of its PROTECT clinical trial of ProTmune, the Company’s next-generation hematopoietic cell graft.

  8. BeyondSpring Announces Initiation Of Phase 3 Clinical Development For Plinabulin For Prevention Of Chemotherapy-Induced Neutropenia

    BeyondSpring Inc. a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company has initiated the Phase 3 portion of Study 105 evaluating its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia (CIN) associated with docetaxel, a cytotoxic chemotherapeutic.

  9. ERT Recognized For Supporting Heart Health In Children

    ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, recently announced that it has been recognized by Simon’s Fund with a Big Heart Award.

  10. Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease

    Abeona Therapeutics Inc. a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced recently that the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program (AAV-CLN1), an AAV-based gene therapy for the treatment of CLN1 disease (infantile and late infantile onset Batten disease).